Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Shareholders in Mithra Pharmaceuticals SA (EBR:MITRA) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts have sharply increased their revenue numbers, with a view that Mithra Pharmaceuticals will make substantially more sales than they'd previously expected.

Following the upgrade, the current consensus from Mithra Pharmaceuticals' three analysts is for revenues of €331m in 2022 which - if met - would reflect a huge increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing €274m of revenue in 2022. The consensus has definitely become more optimistic, showing a very substantial lift in revenue forecasts.

See our latest analysis for Mithra Pharmaceuticals

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Mithra Pharmaceuticals' growth to accelerate, with the forecast 14x annualised growth to the end of 2022 ranking favourably alongside historical growth of 2.8% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 5.4% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Mithra Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They're also forecasting more rapid revenue growth than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Mithra Pharmaceuticals.

Better yet, Mithra Pharmaceuticals is expected to break-even soon - within the next few years - according to analyst forecasts, which would be a momentous event for shareholders. You can learn more about these forecasts, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.